The ingredient of Shihuida is levamlodipine benzenesulfonate, and levamlodipine benzenesulfonate can be combined with metoprolol to increase the efficacy of lowering blood pressure. The main effect of levamlodipine benzenesulfonate is to inhibit the inward flow of calcium ions, and it has a dilating effect on both peripheral large arteries and coronary arteries, which can be clinically used in the treatment of coronary heart disease and hypertension. Metoprolol is a beta-blocker, also has the effect of lowering blood pressure, and can be used for the treatment of tachyarrhythmia. Levamlodipine besylate and metoprolol have no contraindications, and the combination of the two drugs can increase the effect of the drug, hypertension with coronary artery disease, if accompanied by rapid heart rate, the combination of the two drugs is more effective. The adverse effects of levamlodipine benzenesulfonate include lower limb edema, dry stools, flushing, etc. It is forbidden for patients who are allergic to the components of the drug. Adverse reactions to metoprolol include cold extremities, decreased blood pressure, bradycardia, nausea, dizziness, dyspnea, etc. It is contraindicated in patients with allergy to the drug components, second- and third-degree atrioventricular block, cardiogenic shock, bronchial asthma, severe hypotension, and severe bradycardia. When levamlodipine benzenesulfonate and metoprolol are used in combination, the appropriate dosage and usage should be selected under the guidance of a doctor.